Pharmacyclics PCYC-1121-CA A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

8741-CTO
Cancer - Lymphoma
Open